Rocío U.
- Country
- Spain
- Department
- Oncolgy
Research Overview
- Phase III Randomized, Double-Blind Study of Pembrolizumab with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in High-Risk ER+/HER2- Breast Cancer
- C4891002: A Phase 3, Randomized, Open-Label, Multicenter Study Of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib For The Treatment Of Participants With Estrogen Receptor Positive, HER2-Negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease (VERITAC-3)
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 185 of 417 partner sites.
Specializations
HER2-Positive Breast Cancer Research
Specializes in investigating novel therapeutic approaches for HER2-positive breast cancer, with particular focus on early-stage disease and advanced cases. Studies innovative treatment combinations including trastuzumab-based therapies and emerging antibody-drug conjugates.
- Early-stage HER2+ breast cancer treatment
- Neoadjuvant therapy optimization
- Post-treatment residual disease management
HR-Positive/HER2-Negative Breast Cancer
Conducts research in hormone receptor-positive breast cancer treatment strategies, exploring new therapeutic combinations and targeted approaches. Focuses on both early-stage and advanced disease settings with emphasis on endocrine therapy innovations.
- Advanced breast cancer treatments
- Endocrine therapy resistance
- Novel therapeutic combinations
Metastatic Breast Cancer
Investigates treatment approaches for metastatic breast cancer across different subtypes. Studies include evaluation of targeted therapies and immunotherapy combinations for advanced disease stages.
- Treatment resistance mechanisms
- Novel drug development
- Biomarker-driven therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.